Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retatrutide versus placebo in adults with type 2 diabetes mellitus and moderate-to-severe chronic kidney disease on basal insulin
MOH_2025-04-07_013899Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of retatrutide in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) (4 arms), sponsored by Eli Lilly and Company. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on MOH_2025-04-07_013899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-04-07_013899.